Reuters
Published Apr 06, 2020 11:05AM ET
Updated Apr 06, 2020 01:05PM ET
By Doina Chiacu
WASHINGTON (Reuters) - White House trade adviser Peter Navarro on Monday acknowledged that members of the task force dealing with the coronavirus crisis clashed over the efficacy of the malaria drug, hydroxychloroquine, for use against the disease.
Navarro had a heated exchange on Saturday with Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, Axios reported.
Fauci, the nation's top infectious diseases expert, and other top health advisers have argued there is not enough data from the limited studies that have been done to prove the drug is effective against COVID-19, the sometimes deadly respiratory illness caused by the virus.
Navarro has been appointed by U.S. President Donald Trump to oversee the administration's implementation of the Defense Production Act to help produce scarce medical supplies. While acknowledging he has no scientific background, Navarro said he believed the hydroxychloroquine studies done so far were convincing.
"There was that discussion on Saturday," Navarro said in an interview with CNN. "If we didn't have disagreements and debate the Trump administration would not be as strong as it is."
The dispute illustrated the tensions between the White House's scientific and health experts and other policymakers or advisers in the administration with no medical or research training, led by the president himself, who have been pushing the malaria drugs, chloroquine and hydroxycloroquine, for use during the coronavirus crisis.
Trump has made his opinion on the drug well known and personally pressed federal health officials to make them available to treat coronavirus, two sources have told Reuters.
The president has repeatedly pushed the drug as a potential treatment, calling it a "game-changer" with little evidence to support that claim. He touted it again on Sunday, adding "But what do I know? I'm not a doctor."
However, when Fauci, who is a doctor, was asked a question about the drug at the same task force briefing, Trump cut in and blocked him from answering, "Do you know how many times he’s answered that question? Maybe 15."
'TOO SOON TO TELL'
At Saturday's meeting of the task force, Navarro told CNN, "there was unanimous agreement that FEMA would immediately begin surging hydroxy into the hot zones to be dispensed only between a doctor and a patient decision not the federal government." He said there were 29 million tablets of hydroxychloroquine sitting in a warehouse.
Navarro said that patients in the New York hospital system that come in presenting symptoms of COVID-19 are given a cycle of hydroxychloroquine, which may help reduce inflammation caused by the immune system's response to the virus.
A city health official said on Monday that many patients at New York’s 11 public hospitals have been given hydroxycloroquine as part of treatment regimen, but it was too soon to tell if it was effective.
"We’re still looking at the data, but right now we’re willing to try just about anything to save patients," said Dr. Eric Wei, vice President and chief quality officer for NYC Health + Hospitals.
Navarro argued there were now "numerous scientific studies that indicate potential efficacy," including one published in the last few days involving Wuhan, China, where the virus first surfaced, that he said was one of the first randomized studies.
"All my role has been in this is to suggest that we have this in the stockpiles and that you should have that discussion about whether we should surge this in the task force," he said.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.